Top

Published in:

Open Access 01-12-2017 | Letter

A brief comment on vaccinations for opportunistic microorganisms

Authors: Ferhat Arslan, Haluk Vahaboğlu

Published in: Critical Care | Issue 1/2017

Excerpt

We read with interest the manuscript by Rello et al. published in Critical Care [1]. The authors conducted a randomized, placebo-controlled vaccine study against Pseudomonas aeruginosa among intensive care unit (ICU) patients and concluded that vaccination against P. aeruginosa failed to protect the patients from infection with this microorganism. Interestingly, invasive P. aeruginosa infections were more common among the vaccinated population (vaccinated, 39/263; placebo, 6/92; risk ratio (RR) 1.169; 95% confidence interval (CI) 1.027–1.332; one-sided Fischer’s exact test, p = 0.042; Stata 13.1). …

Rello J, Krenn C-G, Locker G, et al. A randomized placebo-controlled phase II study of a pseudomonas vaccine in ventilated ICU patients. Crit Care. 2017;21:22.CrossRefPubMedPubMedCentral

Smillie WG, Duerschner DR. The epidemiology of terminal pneumonia: II. The selectivity of nasopharyngeal bacteria in invasion of the lungs. Am J Hyg. 1947;45:13–8.PubMed

Kneeland YJ, Price KM. Antibiotics and terminal pneumonia. Am J Med. 1960;29:967–79.CrossRefPubMed

Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351:399–403.CrossRefPubMed

Brown SP, Cornforth DM, Mideo N. Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. Trends Microbiol. 2012;20:336–42.CrossRefPubMedPubMedCentral

Freeman GH, Halton JH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951;38(1–2):141–9.CrossRefPubMed

Falkenhorst G, Remschmidt C, Thomas H, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: Systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368.

Priebe G, Goldberg J. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014;13:507–19.CrossRefPubMedPubMedCentral

Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34:1–14.CrossRefPubMed

Title: A brief comment on vaccinations for opportunistic microorganisms
Authors: Ferhat Arslan
Haluk Vahaboğlu
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2017
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-017-1684-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A brief comment on vaccinations for opportunistic microorganisms

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

What is the risk of acquiring bacteria from prior intensive care unit bed occupants?

Hemoglobin concentrations and RBC transfusion thresholds in patients with acute brain injury: an international survey

Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study

Recorded time periods of bispectral index values equal to zero predict neurological outcome after out-of-hospital cardiac arrest

Thoracic ultrasound for pleural effusion in the intensive care unit: a narrative review from diagnosis to treatment

A supplemental intravenous amino acid infusion sustains a positive protein balance for 24 hours in critically ill patients